Therapeutic uses of chemokine variants
AssigneeMerck Serono SA
InventorsAmanda Proudfoot, Jeffrey Shaw, Zoe Johnson
Life of this patent
Estimating the term…
Abstract
Variants of homodimer-forming chemokines, such as human CCL2, having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds and acting as an obligate monomer, can antagonize natural chemokines and have anti-inflammatory activity in vivo. These variants can be used as active ingredient in pharmaceutical compositions for the treatment of inflammatory, autoimmune, or infectious diseases.
Claims12
A method for treating an autoimmune or inflammatory disease comprising the administration of an effective amount of a monomeric variant to an individual having an autoimmune or inflammatory disease,
- wherein Monocyte Chemoattractant Protein 1 (MCP-1) signaling is involved in the autoimmune or inflammatory disease process and said monomeric variant comprises:
- a) SEQ ID NO:
- 2 (CCL2-P8A);
- b) SEQ ID NO:
- 4 (CCL2*-P8A):
- c) SEQ ID NO:
- 2 or SEQ ID NO:
- 4 with the substitution of a Cysteine in position 8, 14 or 17;
- d) SEQ ID NO:
- 2 or SEQ ID NO:
- 4 with the substitution of an Alanine or a Glycine in position 1;
- or
- e) SEQ ID NO:
- 2 or SEQ ID NO:
- 4 with the addition of a Cysteine at the C-terminus.
Dependencies are inferred from the claim text.